4YD Stock Overview
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Nanologica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.44 |
| 52 Week High | kr1.09 |
| 52 Week Low | kr0.40 |
| Beta | 0.64 |
| 1 Month Change | -14.31% |
| 3 Month Change | -26.92% |
| 1 Year Change | -54.76% |
| 3 Year Change | -72.77% |
| 5 Year Change | n/a |
| Change since IPO | -72.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4YD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | 0.4% | 1.8% |
| 1Y | -54.8% | -21.9% | 4.2% |
Return vs Industry: 4YD underperformed the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: 4YD underperformed the German Market which returned 2.8% over the past year.
Price Volatility
| 4YD volatility | |
|---|---|
| 4YD Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4YD's share price has been volatile over the past 3 months.
Volatility Over Time: 4YD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 16 | Andreas Bhagwani | www.nanologica.com |
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide. The company operates through two segments, Drug Development and Chromatography. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA HPLC analytical columns.
Nanologica AB (publ) Fundamentals Summary
| 4YD fundamental statistics | |
|---|---|
| Market cap | €21.56m |
| Earnings (TTM) | -€6.83m |
| Revenue (TTM) | €680.77k |
31.7x
P/S Ratio-3.2x
P/E RatioIs 4YD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4YD income statement (TTM) | |
|---|---|
| Revenue | kr7.95m |
| Cost of Revenue | kr7.49m |
| Gross Profit | kr464.00k |
| Other Expenses | kr80.30m |
| Earnings | -kr79.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 05, 2024
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 5.84% |
| Net Profit Margin | -1,003.92% |
| Debt/Equity Ratio | 558.2% |
How did 4YD perform over the long term?
See historical performance and comparison